Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition
暂无分享,去创建一个
N. Reinmuth | C. Belka | Minglun Li | J. Ricke | M. Unterrainer | W. Kunz | C. Eze | F. Manapov | A. Tufman | J. Taugner | L. Käsmann | L. Mittlmeier | P. Bartenstein